about
p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activityA DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growthCombined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic miceThe Promise of Preventive Cancer VaccinesAre oncoantigens suitable targets for anti-tumour therapy?Vaccines for tumour prevention2H,3H-decafluoropentane-based nanodroplets: new perspectives for oxygen delivery to hypoxic cutaneous tissuesAn integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological preventionIntratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsMicroenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.A mathematical-biological joint effort to investigate the tumor-initiating ability of Cancer Stem Cells.ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult miceMulti-level model for the investigation of oncoantigen-driven vaccination effect.State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?Consensus nomenclature for CD8(+) T cell phenotypes in cancerAntitumor immunization of mothers delays tumor development in cancer-prone offspring.Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice.Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.Vaccination for treatment and prevention of cancer in animal models.Novel insights into Notum and glypicans regulation in colorectal cancerBovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancerSca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice.A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans.Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignanciesThe scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitriesVaccines and other immunological approaches for cancer immunoprevention.DNA vaccination against oncoantigens: A promise.Preclinical vaccines against mammary carcinoma.Xenogene vaccination in the therapy of cancer.The importance of comparative oncology in translational medicine.Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth.Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer.Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.NK cells control breast cancer and related cancer stem cell hematological spread.
P50
Q24306867-4E913FA5-6B76-4F64-B0B0-831155A6560DQ24548511-E0EC0B09-80EA-4317-BC03-CD5818C2CCCDQ24670549-9F3F0267-2518-4CEF-BEF9-7FE00B358A83Q26783742-7A681EFC-4630-4602-80F4-378E57CE12D7Q28240977-5F74B1A6-BD30-42E6-A5A9-77D03F1F6045Q28299036-AF61ED28-3E69-4890-95DF-9D093C014EDEQ30416282-99B6EC32-C867-49AC-B0BC-FA0BD392C91DQ33229377-322911BE-97B3-4F4E-B11F-57012A3A201CQ33645792-89713248-4506-4F08-983F-37C099BF1BA7Q33786788-2F4D74B6-17ED-4F11-9A69-92282DFBEC57Q33851540-248260E9-0075-4D55-9DDD-5A03DA349722Q34128350-36F6E8F4-71C1-4D29-8D12-430DAC1A83C8Q34598522-FF58A02D-28C0-4396-AE04-D2BC6A2A6AF1Q34756500-9DCAF8D3-DB60-4F2F-9021-0B861AFEA1EDQ34787916-F38FD7D5-3027-43F9-BA48-FF4AFCE10BE3Q35798822-F7B8F883-5522-4C95-9EEE-1AD73860FF79Q35799346-A3C86C47-3C92-4E5F-A2E3-2028DE9D58CCQ36393263-77B3DD5C-E91E-4707-987D-91DA322906A1Q36401520-5EB74B7A-6113-40F4-BE94-4882FA3F9869Q36490759-6965D260-B5FB-4A80-AE2C-EBACDD3C9A53Q36562344-838F27E3-5E26-4BC6-BB84-15B4DCD7F6DAQ36821263-2B28EB12-636D-4A51-B109-4094B0918733Q36982130-1EC8E9B1-2533-45EB-9580-E29CB829867DQ37078963-255AF9AC-400B-4EB2-AB6C-47847D644A93Q37137404-77E788E1-5AA6-47AC-9C42-0E8DF490AA8FQ37289084-3950A768-3866-4D89-9B9D-27169C8CC43CQ37294327-11403658-6F43-4645-A5B8-CF8866C81F2EQ37362844-6BD36315-C3CA-4458-9B26-C254E5157C1BQ37691212-7A5A837F-4813-45ED-876B-32CBB1C1B609Q37695012-B64B4A29-86B3-4628-BE35-992A3158FA80Q37710032-05A90F1D-ABA5-4441-B218-386F2076513DQ37821015-4A725387-1702-4953-9EE4-663EB41761F6Q38022032-E8FDA3FA-8694-4864-B29F-E7145971DF8FQ38160252-C2E881E6-47F6-4EAD-B70E-231B9F4A49BBQ38229368-B783957E-AC05-4A10-9FA1-003D448B33DBQ38303454-8EC0CFF8-215B-41A1-BF78-DF46FA735D78Q38627228-53A57B51-BA0A-464D-BB66-D40E88321DABQ38819633-DA67CE77-6DB4-49DA-8574-C89A2B976F05Q38831440-7F3157DF-E787-43F3-B9C2-E54ED6FDF812Q38839126-9EF4FD93-4740-47A4-94D5-C4D04F19E9E1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Federica Cavallo
@ast
Federica Cavallo
@en
Federica Cavallo
@es
Federica Cavallo
@nl
Federica Cavallo
@sl
type
label
Federica Cavallo
@ast
Federica Cavallo
@en
Federica Cavallo
@es
Federica Cavallo
@nl
Federica Cavallo
@sl
prefLabel
Federica Cavallo
@ast
Federica Cavallo
@en
Federica Cavallo
@es
Federica Cavallo
@nl
Federica Cavallo
@sl
P1053
C-5666-2011
P106
P1153
34568031100
P21
P2456
P31
P3829
P496
0000-0003-4571-1060